Basic Information
Oxervate
Regulatory Information
EMEA/H/C/004209
Authorised
July 6, 2017
May 18, 2017
3
October 25, 2024
Company Information
Italy
Via San Martino 12 20122 Milano
DOMPE' FARMACEUTICI SPA
Drug Classification
Orphan MedicineAccelerated Assessment
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults
Overview Summary
This is a summary of the European public assessment report (EPAR) for Oxervate. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Oxervate. For practical information about using Oxervate, patients should read the package leaflet or contact their doctor or pharmacist.